Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

NCT07144254

The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS). The study will also investigate the toxicities of Tegavivint in combination with gemcitabine in patients with relapsed or refractory OS.

Osteosarcoma RecurrentOsteosarcoma in ChildrenRelapsed Osteosarcoma+1 more

Emory University24 participantsStarted Jan 2026

Atlanta, Georgia, United States

COMPLETED

Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma

NCT04651179

A retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment

Osteosarcoma RecurrentOsteosarcoma Metastatic

Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna33 participantsStarted Apr 2020

Milan, Milano, Italy • Candiolo, Turin, Italy • Bologna, Italy +5 more locations

Data from ClinicalTrials.govTerms

Filters

Filters

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma